Position of the Transparency Council – Enhertu (trastuzumab deruxtecan)

At its meeting on 2 January 2023, the Transparency Council adopted position No. 72/2024 on the evaluation of the drug Enhertu (trastuzumab deruxtecan) under the drug program B.9.FM “Treatment of patients with breast cancer (ICD- 10: C50)”

Publication of the position >>